DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 51 filers reported holding DYNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,532,800 | -2.5% | 2,180,000 | +22.5% | 2.61% | -4.3% |
| Q2 2023 | $20,025,000 | +2.3% | 1,780,000 | +4.7% | 2.72% | -2.8% |
| Q1 2023 | $19,584,000 | -21.4% | 1,700,000 | -20.9% | 2.80% | -4.0% |
| Q4 2022 | $24,918,500 | -14.2% | 2,150,000 | -6.0% | 2.92% | -18.3% |
| Q3 2022 | $29,049,000 | +45.8% | 2,287,321 | -21.1% | 3.57% | -2.3% |
| Q2 2022 | $19,923,000 | -24.4% | 2,900,000 | +6.1% | 3.66% | +6.9% |
| Q1 2022 | $26,360,000 | -31.5% | 2,734,392 | -15.5% | 3.42% | -13.8% |
| Q4 2021 | $38,457,000 | -34.6% | 3,234,392 | -10.6% | 3.97% | -6.4% |
| Q3 2021 | $58,779,000 | +36.0% | 3,619,392 | +76.2% | 4.24% | +16.7% |
| Q2 2021 | $43,224,000 | -13.1% | 2,054,392 | -35.9% | 3.63% | -25.2% |
| Q1 2021 | $49,764,000 | +47.7% | 3,204,392 | +99.7% | 4.86% | +68.2% |
| Q4 2020 | $33,692,000 | +4.0% | 1,604,392 | 0.0% | 2.89% | -30.3% |
| Q3 2020 | $32,393,000 | – | 1,604,392 | – | 4.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |